Unlocking the Future of the HER2-Negative Breast Cancer Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the her2-negative breast cancer market size evolved in recent years?
The market size for HER2-negative breast cancer has seen significant growth in recent years. Projected growth for this sector is from $16.29 billion in 2024 to $17.62 billion in 2025, at a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historic period include a surge in breast cancer diagnoses, heightened awareness concerning breast cancer, elevated healthcare expenditure, an aging population, and improvements to healthcare facilities.
What are the predictions for the her2-negative breast cancer market size in the coming years?
We anticipate robust expansion in the HER2-negative breast cancer market over the coming years. The market is projected to reach a value of $23.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Factors influencing this growth during the forecast period may include heightened alcohol consumption, adoption of poor lifestyle choices, an uptick in obesity prevalence, increased tobacco use, and a growing demand for effective treatment methods. Expected trends for the forecast period are advances in diagnostic technology, the introduction of targeted therapies, the inclusion of immunotherapies, approvals by the FDA, and technological advancements.
Get your her2-negative breast cancer market report here!
https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report
What key factors are fueling the growth of the her2-negative breast cancer market?
The increasing instances of breast cancer are anticipated to drive the progress of the HER2-negative breast cancer market. Breast cancer manifests as uncontrolled proliferation of abnormal cells in the breast tissue, typically originating from the ducts or lobules. The growth in breast cancer instances can be linked to factors such as heightened awareness and enhanced screening practices, resulting in earlier and more regular detection. HER2-Negative Breast Cancer contributes significantly to breast cancer research by offering valuable information on distinctive tumor biology and treatment strategies, aiding the creation of more patient-specific therapies. For example, The Centers for Disease Control and Prevention, a governmental agency in the U.S., reported 272,454 fresh cases of breast cancer in females in 2021, with 42,211 females passing away from the disease in 2022. This surge in breast cancer incidences is thus propelling the HER2-negative breast cancer market forward.
How is the global her2-negative breast cancer market divided into key segments?
The HER2-negative breast cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy
2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp
Who are the key firms paving the way for growth in the her2-negative breast cancer market?
Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.
What key trends are currently impacting the her2-negative breast cancer market’s development?
Leading corporations within the HER2-negative breast cancer sector are concentrating on securing requisite permits to roll out new therapies, broaden their product array, and boost their standing within the market. These permits are formal permissions provided by government bodies that enable companies to distribute and advertise their medications or treatments once safety, efficiency, and quality criteria are satisfied. For instance, Genentech Inc., a prominent US biotech firm, in October 2024, obtained FDA clearance to sell Itovebi (inavolisib). This groundbreaking therapy targets advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. Aside from fulfilling FDA criteria, this endorsement allows Itovebi to be combined with palbociclib and fulvestrant, demonstrating a marked enhancement in progression-free survival in patients vis-a-vis standard medications. This innovative treatment regimen underscores the importance of biomarker tests, as this allows for identifying and providing the best treatment options for patients who have limited options.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203
What regions are contributing significantly to the growth of the her2-negative breast cancer market?
North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Anemia and Other Blood Disorder Drugs Global Market Report 2025
Blood Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
